Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) Return on Capital Employed (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Return on Capital Employed for 12 consecutive years, with 0.09% as the latest value for Q3 2025.

  • On a quarterly basis, Return on Capital Employed rose 5.0% to 0.09% in Q3 2025 year-over-year; TTM through Sep 2025 was 0.09%, a 5.0% increase, with the full-year FY2020 number at 0.94%, down 42.0% from a year prior.
  • Return on Capital Employed was 0.09% for Q3 2025 at Theravance Biopharma, up from 0.11% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.09% in Q3 2025 to a low of 0.92% in Q1 2021.
  • A 5-year average of 0.34% and a median of 0.16% in 2025 define the central range for Return on Capital Employed.
  • Peak YoY movement for Return on Capital Employed: tumbled -31bps in 2021, then skyrocketed 57bps in 2023.
  • Theravance Biopharma's Return on Capital Employed stood at 0.79% in 2021, then surged by 82bps to 0.14% in 2022, then dropped by -19bps to 0.17% in 2023, then grew by 13bps to 0.15% in 2024, then skyrocketed by 41bps to 0.09% in 2025.
  • Per Business Quant, the three most recent readings for TBPH's Return on Capital Employed are 0.09% (Q3 2025), 0.11% (Q2 2025), and 0.16% (Q1 2025).